126 материалов по теме, собраны автоматически из проверенных источников
Immune checkpoint inhibitors (ICIs) can promote antitumor responses but can also cause adverse effects that require treatment with immunosuppressive drugs. A new retrospective study by Mass General Brigham Cancer Institute investigators found that patients who received ICIs and multiple immunosuppressive therapies…
Cell therapy weekly: experimental solid cancer CAR-T approved for clinical testing regmednet.com
From Immunotherapy to “Smart” Drugs: Which Technologies Have Transformed Cancer Treatment Over the Past 10 Years UA.NEWS
От иммунотерапии до «умных» лекарств: какие технологии изменили лечение рака за последние 10 лет UA.NEWS
Ученые выявили ген, истощающий иммунные клетки при онкологии и усиливающий эффективность иммунотерапии Gosrf.ru
Immunotherapy, which uses a patient's immune system to treat disease, has increased survival for some adults and children with cancer. However, it has had limited success against many pediatric solid tumors, in part because T cells can become functionally impaired or "exhausted." St. Jude Children's Research Hospital…
Global Bladder Cancer Treatment Market to Reach USD 11.33 Billion by 2034, Driven by Rising Disease Burden, Growing Adoption of Immunotherapy, and Advances in Targeted Cancer Therapies Reports Maximize Market Research Yahoo Finance
Global Bladder Cancer Treatment Market to Reach USD 11.33 Billion by 2034, Driven by Rising Disease Burden, Growing Adoption of Immunotherapy, and Advances in Targeted Cancer Therapies Reports Maximize Market Research PR Newswire
Pancreatic cancer does not respond to most immunotherapies, but RAS inhibitors could alter tumors to make them more sensitive to a novel immunotherapeutic approach. In pancreatic tumors with RAS mutations, RAS inhibitors cause massive cell death and reduce immunosuppression. These changes tend to be temporary because…
Treatment with immune checkpoint inhibitors can significantly increase risk for major adverse cardiovascular events among patients with cancer, including heart failure, myocardial infarction and stroke. A retrospective analysis of more than 30,000 patients showed individuals treated with immune checkpoint inhibitors…
New Immunotherapy Strategy Extends KRAS Inhibitor Response in Pancreatic Cancer Inside Precision Medicine
Sophie Gray-Gaillard Advances Research on T Cells and Cancer Immunotherapy – PICI Oncodaily
For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually moderate or severe, with more than one-third leading to permanent ICI discontinuation, according to a study published online Sept. 8 in ACR Open Rheumatology.
Zolbetuximab and Immunotherapy Across PD-L1 CPS in Advanced Gastric and GEJ Cancer Oncodaily
How immunotherapy changed cancer treatment – and why its impact is still growing UT MD Anderson